$30M Debt Facility Fuels Iantrek's Glaucoma Tech Expansion
Event summary
- $30M debt facility from Trinity Capital to Iantrek for growth capital
- Funding to accelerate commercial expansion of AlloFlo Uveo and pipeline products
- Follows $100M Series C raise in 2025 led by USVP, Sectoral, aMoon, Visionary Ventures
- Proceeds support manufacturing, distribution, and market access initiatives
- Iantrek focuses on bio-interventional ophthalmic surgery for glaucoma treatment
The big picture
Trinity Capital's $30M debt facility underscores confidence in Iantrek's minimally invasive glaucoma treatment technology, following a strong Series C round. The funding positions Iantrek to compete in the surgical ophthalmology space as it scales commercial operations and advances its product pipeline. The deal highlights the growing investment in bio-interventional solutions for chronic eye diseases, with a focus on restoring natural ocular outflow pathways.
What we're watching
- Commercial Execution
- How quickly Iantrek can scale manufacturing and distribution to meet growing physician demand for AlloFlo Uveo.
- Pipeline Development
- The pace at which Iantrek advances its next wave of bio-interventional products through development and regulatory approvals.
- Market Adoption
- Whether Iantrek can broaden physician and patient adoption of its platform through strengthened market access initiatives.
Related topics